ConfidentialConfidentialHarris NesbittFocus on HealthcareHarris NesbittFocus on HealthcareDecember 8, 2005December 8, 2005
2This presentation contains “forward-looking statements” as defined under thefederal securities laws. Actual results could...
4Investment ConsiderationsInvestment ConsiderationsA Leader in Regenerative Medicine – the Next Frontier in MedicineProduc...
Realizing the Potential ofHuman Embryonic Stem CellsRealizing the Potential ofHuman Embryonic Stem Cells
6Stem Cells are a Proven TherapyStem Cells are a Proven TherapyFirst successful bone marrow transplant (BMT) in 1968Tens o...
7The Potential of Human ES Cells - PluripotencyThe Potential of Human ES Cells - Pluripotency
8ES Cells Form Complex TissuesES Cells Form Complex TissuesScience 2002 295: 819PNAS 2003, 100 Suppl 1:11911Intestine Musc...
9The Potential of Human ES CellsThe Potential of Human ES CellsBeating heart cellsBeating heart cells
Regenerative Medicine“The New Frontier”Regenerative Medicine“The New Frontier”
11Regenerative MedicineCuring Devastating DiseaseRegenerative MedicineCuring Devastating Disease800,000Parkinsons patients...
12Growing Legislative SupportGrowing Legislative SupportCalifornia & Proposition 71Voters approve $3.0 billion in funding ...
13The Next Frontier in MedicineThe Next Frontier in Medicine"If the potential of stem cell research is realized, it would ...
ACT Business StrategyACT Business Strategy
15Focused Business StrategyFocused Business StrategyDriving Human ES Cell Therapies to the ClinicSolving Immune Rejection ...
16Driving Human ES Cell Therapies to the ClinicDriving Human ES Cell Therapies to the Clinic
17Driving Human ES Cell Therapies to the ClinicDriving Human ES Cell Therapies to the Clinic
18Driving Human ES Cell Therapies to the ClinicDriving Human ES Cell Therapies to the Clinic
19Our Product Development PathwayOur Product Development PathwayCell Discovery and ValidationFinding Cell Types with Thera...
20Cell Therapy – RPE cellsCell Therapy – RPE cellsAge-related diseases of the eyeOver 10 million cases MDG in U.S.Early fu...
21Cell Therapy – Hemangioblast CellsCell Therapy – Hemangioblast CellsPotential treatment for multiplecardiac and blood di...
22Cell Therapy – Dermal CellsCell Therapy – Dermal CellsUnique capacity of early skin cellsLarge applications in burns, wo...
23Solving Immune Rejection and the Ethical DebateSolving Immune Rejection and the Ethical DebateTwo Significant Challenges...
24Chronic Diseases or Indications Requiring Custom TherapyToday - Somatic Cell Nuclear Transfer (“SCNT”)Tomorrow – Transdi...
25Somatic Cell Nuclear Transfer – “SCNT”Somatic Cell Nuclear Transfer – “SCNT”
26Reduced Complexity LibraryReduced Complexity LibraryACT Reduced Complexity LibraryHLA matched cellline for patientAct 1A...
27Strong IP in Alternative TechnologiesStrong IP in Alternative Technologies10.17.05Scientists Find New Ways to DeriveEmbr...
28No Damage to the EmbryoNo Damage to the Embryo
29Leveraging Proprietary Technology PlatformLeveraging Proprietary Technology Platformescellsescellspatientpatient--specif...
30Expanding Academic Collaborationsand Corporate PartnershipsExpanding Academic Collaborationsand Corporate PartnershipsCo...
31Key Financial InformationKey Financial InformationStrong Cash Position of $16 millionFunding StatusFunded into 2007Poten...
32Senior Management TeamSenior Management TeamMr. William Caldwell, IV, Chief Executive Officer30 Year Career in Managemen...
332005 Corporate Milestones - Achieved2005 Corporate Milestones - AchievedExpanded Senior Management and Scientific TeamRa...
342006 Corporate Milestones - Objectives2006 Corporate Milestones - Objectives“GMP” Cell ProductionDerive Human ES Cells u...
35SummarySummaryA Leader in Regenerative Medicine – the Next Frontier in MedicineProduct Focused – Driving Human ES Cell T...
ConfidentialConfidential
Harris Nesbiti Focus on Healthcare Conference Presentation
Upcoming SlideShare
Loading in …5
×

Harris Nesbiti Focus on Healthcare Conference Presentation

100 views

Published on

12/8/2005

Published in: Technology, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
100
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Harris Nesbiti Focus on Healthcare Conference Presentation

  1. 1. ConfidentialConfidentialHarris NesbittFocus on HealthcareHarris NesbittFocus on HealthcareDecember 8, 2005December 8, 2005
  2. 2. 2This presentation contains “forward-looking statements” as defined under thefederal securities laws. Actual results could vary materially. Factors that couldcause actual results to vary materially are described in our filings with the Securitiesand Exchange Commission.You should pay particular attention to the “risk factors” contained in documents wefile from time to time with the Securities and Exchange Commission. The risksidentified therein, as well as others not identified by the Company, could cause theCompany’s actual results to differ materially from those expressed in any forward-looking statements.Cautionary Statement ConcerningForward-Looking StatementsCautionary Statement ConcerningForward-Looking Statements
  3. 3. 4Investment ConsiderationsInvestment ConsiderationsA Leader in Regenerative Medicine – the Next Frontier in MedicineProduct Focused – Driving Human ES Cell Therapies to the ClinicIntellectual Property – Proprietary Human ES Cell TechnologyHuman Capital – Talented Team of Scientists and ManagementFinancial Resources – Strong Cash Position and Public Currency
  4. 4. Realizing the Potential ofHuman Embryonic Stem CellsRealizing the Potential ofHuman Embryonic Stem Cells
  5. 5. 6Stem Cells are a Proven TherapyStem Cells are a Proven TherapyFirst successful bone marrow transplant (BMT) in 1968Tens of thousands of patients have been cured with BMTHuman embryonic stem cells first isolated in 1998hESC’s have significant potential to treat diseases
  6. 6. 7The Potential of Human ES Cells - PluripotencyThe Potential of Human ES Cells - Pluripotency
  7. 7. 8ES Cells Form Complex TissuesES Cells Form Complex TissuesScience 2002 295: 819PNAS 2003, 100 Suppl 1:11911Intestine Muscle RetinaHair / Skin Cartilage Bone
  8. 8. 9The Potential of Human ES CellsThe Potential of Human ES CellsBeating heart cellsBeating heart cells
  9. 9. Regenerative Medicine“The New Frontier”Regenerative Medicine“The New Frontier”
  10. 10. 11Regenerative MedicineCuring Devastating DiseaseRegenerative MedicineCuring Devastating Disease800,000Parkinsons patients 750,000liver disease patients20,000,000heart disease patients20,000,000 diabetespatients5,000,000epilepsy patients4,000,000Alzheimers patients2,000,000stroke patients300,000kidney disease patients
  11. 11. 12Growing Legislative SupportGrowing Legislative SupportCalifornia & Proposition 71Voters approve $3.0 billion in funding over next ten yearsFormation of CA Institute of Regenerative Medicine (CIRM)Recent awards of initial training grantsOther State InitiativesMA, CT, NJ, NY, IL, FLFederal LegislationBi-partisan House of Representatives Bill H.R. 810Federal Funding for Alternative Methods of Deriving Human ES Cells
  12. 12. 13The Next Frontier in MedicineThe Next Frontier in Medicine"If the potential of stem cell research is realized, it would mean an end to the suffering ofmillions of people. If stem cell research succeeds, there isn’t a person in the country whowon’t benefit, or know somebody who will."Michael J. Fox“[Stem cell research] is the most promising research in healthcare perhaps in this history of theworld and we should not be left behind in this research.”Senator Orin Hatch, (R-Utah)“Science has presented us with a hope called stem-cell research, which may provide ourscientists with answers that have so long been beyond our grasp.”Nancy Reagan“This is not a matter of using a human embryo that has the potential to produce life. Rather,these otherwise discarded embryos have the potential to save lives.”Senator Arlen Specter (R-PA)
  13. 13. ACT Business StrategyACT Business Strategy
  14. 14. 15Focused Business StrategyFocused Business StrategyDriving Human ES Cell Therapies to the ClinicSolving Immune Rejection and the Ethical DebateLeveraging Proprietary Technology PlatformExpanding Collaborations and Corporate Partnerships
  15. 15. 16Driving Human ES Cell Therapies to the ClinicDriving Human ES Cell Therapies to the Clinic
  16. 16. 17Driving Human ES Cell Therapies to the ClinicDriving Human ES Cell Therapies to the Clinic
  17. 17. 18Driving Human ES Cell Therapies to the ClinicDriving Human ES Cell Therapies to the Clinic
  18. 18. 19Our Product Development PathwayOur Product Development PathwayCell Discovery and ValidationFinding Cell Types with Therapeutic PotentialInitial FDA Discussion for Target Indication“GMP” Cell ProductionDerive Human ES Cells under GMPDifferentiate Target Cell Type under GMPPreclinical and Clinical TestingFunctional and Safety Preclinical TestingDevelop Plan with FDA for Human Clinical Trialstarget cell typestarget cell typestarget cell linestarget cell lines
  19. 19. 20Cell Therapy – RPE cellsCell Therapy – RPE cellsAge-related diseases of the eyeOver 10 million cases MDG in U.S.Early functional tests show therapeuticpotentialGMP cell production – next step
  20. 20. 21Cell Therapy – Hemangioblast CellsCell Therapy – Hemangioblast CellsPotential treatment for multiplecardiac and blood disordersPublished data showstherapeutic potential in mousemodelLarge market potentialIn cell discovery nowCirculation Research 2004, 94: 820
  21. 21. 22Cell Therapy – Dermal CellsCell Therapy – Dermal CellsUnique capacity of early skin cellsLarge applications in burns, woundrepair and surgeryIn cell discovery now
  22. 22. 23Solving Immune Rejection and the Ethical DebateSolving Immune Rejection and the Ethical DebateTwo Significant Challenges to Regenerative Medicine TodaySolving Rejection of Cell Therapies by a Patient’s Immune SystemAddressing the Ethical Debate Surrounding the Derivation of HumanES CellACT Uses Proprietary Cellular Reprogramming to Address BothChallenges
  23. 23. 24Chronic Diseases or Indications Requiring Custom TherapyToday - Somatic Cell Nuclear Transfer (“SCNT”)Tomorrow – TransdifferentiationResult - a custom-tailored, patient-specific cell therapy for patientAcute Injuries or Indications Requiring Immediate TherapyTomorrow – Our Reduced Complexity Library (“RCL”)Result – cell therapies for the immediate treatment of acute injuries which willprovide a close match for most patientsSolving Immune Rejection – CellularReprogramming for “Chronic versus Acute”Solving Immune Rejection – CellularReprogramming for “Chronic versus Acute”
  24. 24. 25Somatic Cell Nuclear Transfer – “SCNT”Somatic Cell Nuclear Transfer – “SCNT”
  25. 25. 26Reduced Complexity LibraryReduced Complexity LibraryACT Reduced Complexity LibraryHLA matched cellline for patientAct 1Act 1Act 2Act 2Act 5Act 5Act 6Act 6Act 7Act 7Act 3Act 3Act 8Act 8Act 4Act 4
  26. 26. 27Strong IP in Alternative TechnologiesStrong IP in Alternative Technologies10.17.05Scientists Find New Ways to DeriveEmbryonic Stem Cells- ForbesScientists Devise New Stem CellMethods to Ease Concerns- The New York Times
  27. 27. 28No Damage to the EmbryoNo Damage to the Embryo
  28. 28. 29Leveraging Proprietary Technology PlatformLeveraging Proprietary Technology Platformescellsescellspatientpatient--specificspecifichemangioblasthemangioblastdermaldermalALTERNATIVES / PGDTRADITIONAL ES CELLSCELL DIFFERENTIATIONHISTOCOMPATIBILITY / SCNTTRANSDIFFERENTIATIONTECHNOLOGIESTECHNOLOGIESINTELLECTUAL PROPERTYINTELLECTUAL PROPERTYSCIENTIFIC TEAMSCIENTIFIC TEAMRCLRCLescellsescellsRPERPE
  29. 29. 30Expanding Academic Collaborationsand Corporate PartnershipsExpanding Academic Collaborationsand Corporate PartnershipsCollaboration potential:•Existing scientific andacademic relationships•CA Proposition 71•Large BIO / PharmaDIFFERENTIATION/COW OOCYTEHISTOCOMPATIBILITY/SCNTpatientpatient--specificspecificALTERNATIVE/PGDTRADITIONAL ES CELLS CELL DIFFERENTIATIONrperpedermaldermalhemangioblasthemangioblastrclrclescellsescellsPatientPatient--specificspecificTRANSDIFFFERENTIATIONHISTOCOMPATIBILITY/SCNTTECHNOLOGIESTECHNOLOGIESINTELLECTUAL PROPERTYINTELLECTUAL PROPERTYSCIENTIFIC TEAMSCIENTIFIC TEAM
  30. 30. 31Key Financial InformationKey Financial InformationStrong Cash Position of $16 millionFunding StatusFunded into 2007Potential additional $8.875 million in Convertible Notes – Funding into 2008Conversion of notes at $4.60 per share stock pricePublic Market StatusOTC-BB:ACTCApply for listing on Amex or NASDAQ Capital MarketRecent share price of $2.10 - 2.75Approximate fully-diluted market cap of $125 - 150 million
  31. 31. 32Senior Management TeamSenior Management TeamMr. William Caldwell, IV, Chief Executive Officer30 Year Career in Management and FinanceDr. Michael West, Chairman, Chief Scientific Officer and PresidentFounder of Geron and ACTDr. Robert Lanza, VP of Medical & Scientific Development25 Year Career in Biomedical and Scientific ResearchMr. James Stewart, SVP, Chief Financial Officer25 Year Career in Accounting, FinanceMr. Jon Atzen, SVP, General Counsel15 Year Legal Career in Corporate and Securities Law
  32. 32. 332005 Corporate Milestones - Achieved2005 Corporate Milestones - AchievedExpanded Senior Management and Scientific TeamRaised over $25 million in capitalSeries A Financing of $8.0 million in JanuaryConvertible Note Financing of $17.75 million in SeptemberFormed California CollaborationsDefined Product Areas of FocusRetinal, Dermal and HemangioblastsPublished on Alternatives for Derivation of ES Cells – Nature 2005
  33. 33. 342006 Corporate Milestones - Objectives2006 Corporate Milestones - Objectives“GMP” Cell ProductionDerive Human ES Cells under “GMP”Differentiate and Scale Production of “GMP” cellsLaunch Preclinical and Clinical PlanRecruit Senior Clinical ExecutiveConduct Preclinical Testing of “GMP” cellsWork with FDA to expedite human clinical trialsExpand Technology Platform with Scientific BreakthroughsAchieve Listing on AMEX or NASDAQ Capital MarketAnnounce Corporate Partnership
  34. 34. 35SummarySummaryA Leader in Regenerative Medicine – the Next Frontier in MedicineProduct Focused – Driving Human ES Cell Therapies to the ClinicIntellectual Property - Proprietary Human ES Cell TechnologyHuman Capital – Talented Team of Scientists and ManagementFinancial Resources – Strong Cash Position and Public Currency
  35. 35. ConfidentialConfidential

×